ArticleFrontiers in public health2025
Global burden of age-related macular degeneration (1990-2021): trends, age-sex disparities, and socioeconomic dynamics from the GBD study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cynarin Alleviates Sodium Iodate-Induced Retinal Pigment Epithelium Injury by Regulating Oxidative Stress and Inflammation.Biomolecules · 2026Article
- Visible Light Optical Coherence Tomography Reveals Aging at the Retinal Pigment Epithelium-Bruch's Membrane Interface.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to assess the global burden of Age-related macular degeneration (AMD) across countries, regions, and age groups by sex, sociodemographic index (SDI) level, and risk factors from 1990 to 2021, using newly updated data from the Global Burden of Disease (GBD) study. The focus was on age-related disparities in AMD burden by sex and SDI. Methods: This population-based study utilized AMD data from GBD 2021 (1990-2021). The burden was evaluated using the number of cases, prevalence rates per 100,000 population, and trends in years lived with disability (YLDs) and prevalence, assessed through average annual percentage changes (AAPCs) and estimated annual percentage changes (EAPCs). Results: Globally, AMD prevalence increased from 364,000 cases in 1990 to 806,000 in 2021 (+121%), while YLDs rose from 30,000 to 58,000 (+91%). However, age standardized prevalence and YLD rates (ASPRs and ASYRs) significantly declined (EAPCs: -0.26 and -0.94, respectively). Regional analyses revealed that low SDI regions (e.g., sub-Saharan Africa) bore the highest AMD burden (ASPR: 139.9 per 100,000) and exhibited a younger age distribution, with a significantly higher proportion of cases in individuals aged 55-74 years. In contrast, high SDI regions (e.g., high-income Asia-Pacific) had a concentration of cases among those aged 70 years or older. While medium SDI regions accounted for one-third of global cases in 2021, age-standardized rates declined most slowly in low SDI regions (EAPC: -1.03) and even trended upward in some countries. AMD cases peaked globally at ages 65-69, yet prevalence was highest among those over 85 years (1,349.9 per 100,000), with women generally experiencing a higher burden than men. These findings highlight distinct regional patterns, with younger disease profiles in low SDI regions and aging-driven increases in high SDI regions, underscoring the need for targeted prevention and control strategies. Conclusion: Although global efforts over the past 30 years have led to a decline in AMD prevalence rates and YLDs, the absolute number of cases and YLDs continues to rise, driven by age, sex, socioeconomic status, and geographic location. These findings provide an epidemiological basis for developing global public health strategies to address these ongoing challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.